Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults
JAMA · 2026
DOI: 10.1001/jama.2025.26902 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, 2026. Verfasst von Timothy J Savage und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Amoxicillin, Amoxicillin-Potassium Clavulanate Combination, Sinusitis, Coinfection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCEZID CDC HHS.
Abstract (Originalsprache)
Importance Acute sinusitis has the highest rate of antibiotic prescribing in adults younger than 65 years. There is no consensus regarding whether amoxicillin-clavulanate or amoxicillin should be first-line treatment for uncomplicated acute sinusitis in adults.
Objective
To compare the risk of treatment failure and adverse events between standard-dose amoxicillin-clavulanate vs standard-dose amoxicillin for acute sinusitis in adults. Design, Setting, and Participants New-user, active comparator retrospective cohort study using a nationwide health care utilization database comparing amoxicillin-clavulanate vs amoxicillin for adults aged 18 to 64 years with outpatient acute sinusitis. Patients with a new acute sinusitis diagnosis between January 1, 2018, and December 1, 2023, were eligible. Statistical analysis was conducted between July and November 2025. Propensity score matching was used to help mitigate confounding. Exposures Standard-dose amoxicillin-clavulanate (875 mg-125 mg twice daily) or standard-dose amoxicillin (875 mg twice daily or 500 mg 3 times daily). Main Outcomes and Measures The primary outcome was treatment failure, defined as the first occurrence of a new antibiotic dispensation (with or without an outpatient visit), emergency department or inpatient encounter for acute sinusitis, or inpatient encounter for a sinusitis complication assessed 1 to 14 days after treatment initiation. Antibiotic-associated adverse events and secondary infections were also assessed.
Results
The full cohort included 521 244 eligible patients. After propensity score matching, there were 234 608 patients (117 304 patients per group; 65.5% female; median [IQR] age, 43 [31-54] years). Treatment failure occurred in 3.1% of patients overall, with 0.03% requiring an emergency department or inpatient encounter. There was no observed difference in the risk of treatment failure between the amoxicillin-clavulanate vs amoxicillin groups (3.0% vs 3.1%; risk ratio [RR], 0.96 [95% CI, 0.92-1.01]), which was consistent across sensitivity analyses. There was no difference in antibiotic-associated adverse events (1.3% vs 1.2%; RR, 1.04 [95% CI, 0.97-1.12]). The risk of secondary infections was higher for amoxicillin-clavulanate vs amoxicillin, including yeast infections (1.1% vs 0.8%; RR, 1.40 [95% CI, 1.29-1.53]) and Clostridioides difficile infections (0.04% vs 0.02%; RR, 2.14 [95% CI, 1.29-3.54]). Conclusions and Relevance In this observational study of patients aged 18 to 64 years with acute sinusitis treated in the outpatient setting with standard-dose amoxicillin-clavulanate or standard-dose amoxicillin, there was no observed difference in treatment failure. Amoxicillin-clavulanate was associated with a higher, albeit rare, risk of adverse events. These findings suggest standard-dose amoxicillin may be a preferred first-line treatment for adults with uncomplicated acute sinusitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Division of Infectious Diseases, John T. Milliken Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
- Department of Surgery, Public Health Sciences Division, Washington University School of Medicine, St Louis, Missouri.
- Division of Infectious Disease, Department of Pediatrics, University of Washington, Seattle.
Förderung
- NICHD NIH HHS
- NCEZID CDC HHS
Zitieren
APA
Savage, T. J., Butler, A. M., Kronman, M. P., Durkin, M. J., Sreedhara, S. K., Kabbani, S., Hicks, L. A., & Huybrechts, K. F. (2026). Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults. JAMA. https://doi.org/10.1001/jama.2025.26902
Vancouver
Savage TJ, Butler AM, Kronman MP, Durkin MJ, Sreedhara SK, Kabbani S, et al. Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults. JAMA. 2026. doi:10.1001/jama.2025.26902
BibTeX
@article{Savage2026,
author = {Savage, Timothy J and Butler, Anne M and Kronman, Matthew P and Durkin, Michael J and Sreedhara, Sushama Kattinakere and Kabbani, Sarah and Hicks, Lauri A and Huybrechts, Krista F},
title = {Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2025.26902}
}
EUVIMED